Anixa Biosciences Inc (NASDAQ:ANIX – Get Free Report) CEO Amit Kumar bought 5,000 shares of Anixa Biosciences stock in a transaction that occurred on Monday, July 27th. The stock was purchased at an average cost of $3.44 per share, with a total value of $17,200.00. Following the completion of the acquisition, the chief executive officer directly owned 652,000 shares in the company, valued at $2,242,880. This represents a 0.77% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Amit Kumar also recently made the following trade(s):
- On Friday, July 24th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.73 per share, with a total value of $11,190.00.
- On Monday, July 20th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.46 per share, with a total value of $17,300.00.
- On Monday, July 27th, Amit Kumar acquired 3,188 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.37 per share, for a total transaction of $10,743.56.
- On Friday, July 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.04 per share, for a total transaction of $15,200.00.
- On Friday, June 12th, Amit Kumar bought 21,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $2.50 per share, with a total value of $52,500.00.
Anixa Biosciences Stock Performance
ANIX stock opened at $3.48 on Thursday. The firm has a fifty day moving average price of $2.94 and a 200 day moving average price of $2.92. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46. The firm has a market cap of $118.39 million, a PE ratio of -11.23 and a beta of 0.59.
Analyst Ratings Changes
Several brokerages have recently issued reports on ANIX. Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a research report on Wednesday, June 17th. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Zacks Research upgraded Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Finally, HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.
Get Our Latest Stock Analysis on Anixa Biosciences
Institutional Investors Weigh In On Anixa Biosciences
Hedge funds and other institutional investors have recently made changes to their positions in the company. 683 Capital Management LLC bought a new stake in shares of Anixa Biosciences in the 4th quarter worth about $355,000. ExodusPoint Capital Management LP bought a new position in Anixa Biosciences during the 4th quarter valued at about $293,000. Susquehanna International Group LLP raised its position in Anixa Biosciences by 378.4% in the 3rd quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after purchasing an additional 63,584 shares during the period. Virtu Financial LLC purchased a new stake in Anixa Biosciences in the 4th quarter worth about $161,000. Finally, State Street Corp lifted its stake in Anixa Biosciences by 32.0% in the fourth quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after purchasing an additional 38,540 shares during the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.
About Anixa Biosciences
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Read More
- Five stocks we like better than Anixa Biosciences
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
